CST, 97845S, ZMYND8 Antibody

Polyclonal Antibody for studying RACK7. Validated for Western Blotting,Immunoprecipitation. Highly specific and rigorously validated in-house, ZMYND8 Antibody (CST #97845) is ready to ship. Product Usage Information Western Blotting: 1:1000 Immunoprecipitation: 1:50 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting, Immunoprecipitation Specificity / Sensitivity ZMYND8 Antibody recognizes endogenous levels of total ZMYND8 protein. Species Reactivity: Human, Monkey Source / Purification Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human ZMYND8 protein. Antibodies are purified by protein A and peptide affinity chromatography. Background Zinc finger MYND domain-containing protein 8 (ZMYND8), also referred to as receptor for activated C-kinase 7 (Rack7) and protein kinase C-binding protein 1 (PRKCBP1), is a DNA damage response protein and a transcriptional regulator that is a close homolog of ZMYND11 (BS69) (1). ZMYND8 binds to H3K36me2 and H4K16ac, two histone marks associated with active transcription (2). This protein is targeted to sites of DNA damage within actively transcribed genes, and recruits the H3K4me3-specific histone demethylase KDM5A/JARID1A and nucleosome remodeling and histone deacetylation (NuRD) complex (1-3). Together, these protein complexes mediate transcriptional repression and allow for subsequent double-strand break repair via homologous recombination. ZMYND8 contains a bromodomain and a PWWP domain near its N-terminus, and a MYND domain towards the C-terminus, the latter of which mediates interaction with the NuRD complex (1). ZMYND8 also functions to recruit the H3K4me3-specific histone demethylase KDM5C/JARID1C to enhancer and super-enhancer regions, and functions as a negative regulator of gene expression (4). ZMYND8 and JARID1C are both putative tumor suppressor proteins, and knockdown of either of these proteins leads to derepression of S100 oncogenes (1). ZMYND8 expression is altered in breast and cervical cancer (4,5), and has been found to be translocated with RELA in at least one patient with acute erythroid leukemia (6). Knockdown of ZMYND8 expression in breast cancer cell lines increases anchorage-independent cell growth, cell migration and invasion, and tumor growth in mouse xenograft models (4). Alternate Names CTCL tumor antigen se14-3; CTCL-associated antigen se14-3; cutaneous T-cell lymphoma associated antigen se14-3; Cutaneous T-cell lymphoma-associated antigen se14-3; KIAA1125; MGC31836; MYND-type zinc finger-containing chromatin reader ZMYND8; PKCB1; predicted protein of HQ2893; PRKCBP1; PRO2893; protein kinase C binding protein 1; Protein kinase C-binding protein 1; RACK7; zinc finger MYND domain containing protein 8; Zinc finger MYND domain-containing protein 8; zinc finger MYND-type containing 8; zinc finger, MYND-type containing 8; ZMYND8 Specification REACTIVITY: H Mk SENSITIVITY: Endogenous MW (kDa): 180 SOURCE: Rabbit